National Journal of Physiology

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  12 (2024)
Volume  11 (2023)
Volume  10 (2022)
Volume  9 (2021)
Volume  8 (2020)
Volume  7 (2019)
Volume  6 (2018)
Volume  5 (2017)
Volume  4 (2016)
Related articles

VOLUME 5 , ISSUE 1 ( January-June, 2017 ) > List of Articles

ORIGINAL RESEARCH ARTICLE

Biochemical changes in patients of syndrome “Z” after anti-oxidant treatment

Kanimozhi S, Saravanan A, Ravi K

Keywords : metabolic syndrome, N-acetylcysteine, oxidative stress, sleep apnea

Citation Information : S K, A S, K R. Biochemical changes in patients of syndrome “Z” after anti-oxidant treatment. 2017; 5 (1):10-19.

DOI: 10.5005/NJP-11056-05_01_03

License: CC BY-NC 4.0

Published Online: 01-06-2017

Copyright Statement:  Copyright © 2017; NA


Abstract

Background: Syndrome “Z” refers to the co-occurrence of obstructive sleep apnea (OSA) and metabolic syndrome (MS). We had reported previously that in patients with OSA syndrome (OSAS), oral intake of N-acetylcysteine (NAC) improved their sleep parameters by decreasing oxidative stress. The present study reports the effect of NAC on some components of MS in these patients. Materials and methods: Twenty patients with symptoms suggestive of OSAS and MS underwent overnight polysomnography for confirmation of diagnosis of OSAS. Subsequently, all patients received either NAC (n=10, 600 mg thrice daily) or placebo (n=10) for 30 days. Fasting venous samples were collected and analyzed before and after specific treatments. Results: In the NAC group, after the treatment period, compared to their baseline values, there were significant decreases in serum homocysteine, insulin resistance, triglycerides, total cholesterol and LDL cholesterol levels. A significant increase in serum thiol levels as well as a significant decrease in systolic blood pressure was also observed. Such effects were not seen in the placebo treated group. Conclusion: Oral intake of NAC for one month showed therapeutic potential in the 20 patients of syndrome “Z in our study. This can form the base for large multicentric randomized control trials to extrapolate the results to the general population.

PDF Share
PDF Share
  1. Shahar E, Whitney CW, Redline S, et al. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med. 2001;163:19-25.
  2. Sharma SK, Kumpawat S, Banga A, Goel A. Prevalence and risk factors of obstructive sleep apnea syndrome in a population of Delhi, India. Chest 2006;130:149-56.
  3. Lam JC, Sharma SK, Lam B. Obstructive sleep apnoea: Definitions, epidemiology and natural history. Indian J Med Res. 2010;131:165-70.
  4. Golbidi S, Badran M, Ayas N, Laher I. Cardiovascular consequences of sleep apnea. Lung. 2012 Apr l;190(2):113-32.
  5. Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: a population health perspective. American journal of respiratory and critical care medicine. 2002 May l;165(9):1217-39.
  6. Reaven GM: Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
  7. Wilcox I, McNamara SG, Collins FL, Grunstein RR, Sullivan CE. Syndrome “Z”: the interaction of sleep apnea, vascular risk factors and heart disease. Thorax 1998; 53 (Suppl 3): S25-8.
  8. Sharma SK, Reddy EV, Sharma A, Kadhiravan T, Mishra HK, Sreenivas V, et al. Prevalence and risk factors of syndrome Z in urban Indians. Sleep Med. 2010;11:562-8.
  9. Agrawal S, Sharma SK, Sreenivas V, Lakshmy R. Prevalence of metabolic syndrome in a north Indian hospital-based population with obstructive sleep apnoea. Indian J Med Res. 2011;134:639-44.
  10. Barcelo A, Barbe F, de la Pena M. Antioxidant status in patients with sleep apnoea and impact of continuous positive airway pressure treatment. Eur Respir J. 2006;27:756-60.
  11. McCord JM. The evolution of free radicals and oxidative stress. Am J Med. 2000;108:652-59.
  12. Undurti N Das. Metabolic syndrome is a low-grade systemic inflammatory condition. Expert Rev Endocrinol Metab. 2010:5(4):577-92.
  13. Teramoto S, Yamamoto H, Yamaguchi Y, Namba R, Ouchi Y. Obstructive Sleep Apnea Causes Systemic Inflammation And Metabolic Syndrome. Chest 2005;127(3):1074-1075.
  14. Barcelo A, Miralles C, Barbe F. Abnormal lipid peroxidation in patients with sleep apnoea. Eur Respir J. 2000; 16:644-47.
  15. Lavie P, Herer P and Hoffstein V. Obstructive sleep apnea as a risk factor for hypertension: Population study. Br Med J. 2000;320:479-82.
  16. Singh TD, Patial K, Vijayan VK, Ravi K. Oxidative stress and obstructive sleep apnoea syndrome. Indian J Chest Dis Allied Sci 2009;51:217-24.
  17. Sadasivam K, Patial K, Vijayan VK, Ravi K. Antioxidant treatment in obstructive sleep apnoea syndrome. Indian J Chest Dis Allied Sci 2011;53:153-62.
  18. Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 1991;14:540-5.
  19. Hypertension guidelines. http://guidance.nice.org.uk/CG127/NICE Guidance/pdf/English
  20. Saunders WB and Philadelphia PA. Clinical guide to laboratory tests. 2nd ed: 1990. p. 246.
  21. Bonger A, Garica-Webb P. C-Peptide measurement: Methods and clinical utility. Critical reviews in clinical laboratory science. 1984;19:297.
  22. Katsuki A, Sumida Y. Homeostasis model assessment is a reliable indicator of insulin resistance during follow-up of patients with type 2 diabetes. Diabetes Care. 2001;24:362-65.
  23. Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys. 1959;82(l):70-7.
  24. Frantzen F, Faaren AL, Alfheim I, Nordhei AK. An enzyme conversion immunoassay for determining total homocysteine in plasma or serum. Clin Chern. 1998;44:311-316.
  25. Sundrehagen E. Axis Biochemicals ASA. Enzymatic essay for homocysteine and a kit. EP 623174/US5631127.
  26. Bairaktari E, Hatzidimou K, Tzallas C, et al. Estimation of LDL cholesterol based on the Friedewald formula and on apo B levels. Clin Biochem. 2000;33:549-55.
  27. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) JAMA 2001;285:2486-97.
  28. WHO Expert Consultation. Appropriate bodymass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363: 157-63. [Erratum, Lancet 2004;363:902.]
  29. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991;324:1149-55.
  30. Atmaca G. Antioxidant effects of sulfur-containing amino acids. Yonsei Med J. 2004;45:776-88.
  31. Parish JM, Adam T, Facchiano L. Relationship of Metabolic Syndrome and Obstructive Sleep Apnea. J Clin Sleep Med: 2007;3(5):467-472.
  32. Davies RJ, Belt PJ, Roberts SJ, Ali NJ, Stradling JR. Arterial blood pressure responses to graded transient arousal from sleep in normal humans. J Appl Physiol. 1993;24:1123-30.
  33. Millman RP, Redline S, Carlisle CC, Assaf AR, Levinson PD. Daytime hypertension in obstructive sleep apnoea: prevalence and contributing factors. Chest. 1991;99:861-66.
  34. McQuillan LP, Leung GK, Marsden PA. Hypoxia inhibits expression of eNOS via transcriptional and post-transcriptional mechanisms. Am J Physiol. 1994;267:H1921-27.
  35. Schulz R, Mahmoudi S, Hattar K, Sibelius U, Olschewski H, Mayer K, et al. Enhanced release of superoxide from polymorphonuclear neutrophils in obstructive sleep apnea. Impact of continuous positive airway pressure therapy. Am J Respir Crit Care Med. 2000;162:566-70.
  36. Rauchova H, Pechan O, kunes J. Chronic N-acetylcysteine administration prevents development of hypertension in N-nitro-l-arginine Methyl ester-treated rats: the role of Reactive oxygen species. Hypertens Res. 2005; 28:5.
  37. Girouard H, Chulak C, LeJossec M, Lamontagne D, de Champlain J. Vasorelaxant effects of the chronic treatment with melatonin on mesenteric artery and aorta of spontaneously hypertensive rats. J Hypertens. 2001;19:1369-77.
  38. Girouard H, Chulak C, LeJossec M, Lamontagne D, de Champlain J. Chronic antioxidant treatment improves sympathetic functions and beta-adrenergic pathway in the spontaneously hypertensive rats. J Hypertens. 2003; 21:179-88.
  39. Bergamaschi CT, Campos RR, Lopes OU: Rostral ventrolateral medulla: a source of sympathetic activation in rats subjected to long-term treatment with L-NAME. Hypertension. 1999; 34: 744-47.
  40. Bergamaschi CT, Campos RR, Lopes OU: Role of rostral ventrolateral medulla in maintenance of blood pressure in rats with Goldblatt hypertension. Hypertension. 1995; 26: 1117-20.
  41. Kunes J, Dobes Z, Zicha J: Chronic N-acetylcysteine treatment prevents the development of salt hypertension in immature Dahl rats. J Hypertens. 2004; 22(1):S336.
  42. Loscalzo J. The oxidant stress of hyperhomocysteinemia. J. Clin. Invest. 1996;98:5-7.
  43. Shi SS, Day RM, Halpner AD, Blumberg JB, Suzuki YJ. Homocysteine and a-lipoic acid regulate p44/42 MAP kinase phosphorylation in NIH/3T3 cells. Antiox. Redox. Signal. 1999;1:123-28.
  44. Freedman JE, Loscalzo J, Benoit SE, Valeri CR, Barnard MR, Michelson AD. Decreased platelet inhibition by nitric oxide in two brothers with a history of arterial thrombosis. J. Clin. Invest. 1996;97:979-87.
  45. Jordan W, Berger C, Cohrs S, Rodenbeck A, Mayer G, Niedmann P, et al. CPAP-therapy effectively lowers serum homocysteine in obstructive sleep apnea syndrome. J. Neural. Transm. 2004;111:683-89.
  46. Yilmaz H, Sahin S, Sayar N, Tangurek B, Yilmaz M, Nurkalem Z, et al. Effects of folic acid and N-acetylcysteine on plasma homocysteine levels and endothelial function in patients with coronary artery disease. Acta Cardiol. 2007;62:579-85.
  47. Chung, K. Generation of free radical by interaction of iron with thiols in human plasma and its possible significance. Thromb Res. 2005;116:157-64.
  48. Punjabi NM, Sorkin JD, Katzel LI, Goldberg AP, Schwartz AR, Smith PL. Sleep disordered breathing and insulin resistance in middle aged and overweight men. Am J Respir Crit Care Med. 2002;165:677-82.
  49. Ip MS, Lam B, Ng MM, Lam WK, Tsant KW, Lam KS. Obstructive sleep apnea is independently associated with insulin resistance. Am J Respir Crit Care Med. 2002;165:670-6.
  50. Prentice AM and Jebb SA. Beyond Body Mass Index. Obesity Reviews. 2001 August; 2(3): 141-7.
  51. Song D, Hutchings S, Catherine C, Pang Y. Eur J Pharmacol. 2005;508: 205-10.
  52. Kilic-Okman T, Kucuk M. N-acetyl-cysteine treatment for polycystic ovary syndrome. Int J Gynecol Obstet. 2004;85:296-97.
  53. Brizzi P, Tonolo G, Carusillo F, Malaguarnera M, Maioli M., Musumeci S. Plasma lipid composition and LDL oxidation. Clin Chem Lab Med. 2003;41, 56-60.
  54. Diniz YS, Rocha KK et al. Effects of N-acetylcysteine on sucrose-rich diet-induced hyperglycaemia, dyslipidemia and oxidative stress in rats. Eur J Pharmacol. 2006;14;543(l-3):151-7.
PDF Share
PDF Share

© 2026. Jaypee Brothers Medical Publishers (P) Ltd. | All Rights Reserved.